Clinical meaning
the clinician applies advanced infectious disease management principles including antimicrobial resistance mechanisms, pharmacokinetic/pharmacodynamic optimization, and stewardship. Bacterial resistance develops through multiple mechanisms: enzymatic inactivation (beta-lactamases including ESBLs and carbapenemases hydrolyzing beta-lactam antibiotics), target modification (altered penicillin-binding proteins in MRSA, ribosomal methylation conferring macrolide resistance), efflux pumps (actively transporting antibiotics out of the bacterial cell), and decreased permeability (porin channel mutations limiting antibiotic entry in gram-negative bacteria). The clinician applies PK/PD principles to antimicrobial dosing: time-dependent killing (beta-lactams -- efficacy determined by percentage of dosing interval above MIC, supporting extended or continuous infusions), concentration-dependent killing (aminoglycosides, fluoroquinolones -- efficacy determined by peak concentration to MIC ratio), and concentration-dependent with time dependence (vancomycin -- AUC/MIC ratio target of 400-600). The clinician interprets culture and sensitivity results, selects empiric therapy based on most likely pathogens and local antibiogram data, narrows spectrum based on culture results, monitors therapeutic drug levels for vancomycin and aminoglycosides, and implements antimicrobial stewardship principles.